A Wagle Shukla1, R Brown2, K Heese2, J Jones3, R L Rodriguez1, I M Malaty1, M S Okun1, B M Kluger2. 1. a 1 Department of Neurology , University of Florida , Gainesville , FL , USA. 2. b 2 Department of Neurology , University of Colorado , Aurora , CO , USA. 3. c 3 Department of Clinical Health Psychology , University of Florida , Gainesville , FL , USA.
Abstract
BACKGROUND: Nonmotor symptoms in dystonia are increasingly recognized to impair the quality of life. The primary objective of this study was to determine the prevalence of fatigue and sleep disturbances in dystonia and to ascertain their impact on quality of life using standardized questionnaires. METHODS: Dystonia patients presenting to a Botulinum toxin clinic were prospectively administered Fatigue Severity Scale (FSS), Multidimensional Fatigue Inventory (MFI), Epworth Sleepiness Scale (ESS) and Parkinson's Disease Sleep Scale (PDSS) for assessment of fatigue and sleep disturbances. Health-related Quality of life (HRQOL) was determined using MOS SF-36 scale and depressive symptoms were assessed using the Beck Depression Inventory II. RESULTS: Ninety-one patients with dystonia participated (66 women, 25 men, mean age 60 ± 17 years). Nine subjects had generalized dystonia, 18 segmental dystonia and 64 had focal dystonia. Moderate to severe fatigue was present in 43% of the cohort (FSS), excessive daytime somnolence in 27% (ESS) and other sleep disturbances in 26% (PDSS). FSS and MFI scores correlated significantly with HRQOL even when controlled for depression and sleep disturbances. Excessive daytime somnolence and nocturnal sleep disturbances correlated significantly with the HRQOL; however, these effects were not seen for daytime somnolence when controlled for depression. Psychometric testing found adequate reliabilities and convergent validities for both fatigue and sleep scales. CONCLUSION: Fatigue and sleep disturbances revealed high prevalence rates in this large, first of its dystonia study. They negatively impacted the quality of life even when controlled for comorbid depression.
BACKGROUND: Nonmotor symptoms in dystonia are increasingly recognized to impair the quality of life. The primary objective of this study was to determine the prevalence of fatigue and sleep disturbances in dystonia and to ascertain their impact on quality of life using standardized questionnaires. METHODS:Dystoniapatients presenting to a Botulinum toxin clinic were prospectively administered Fatigue Severity Scale (FSS), Multidimensional Fatigue Inventory (MFI), Epworth Sleepiness Scale (ESS) and Parkinson's Disease Sleep Scale (PDSS) for assessment of fatigue and sleep disturbances. Health-related Quality of life (HRQOL) was determined using MOS SF-36 scale and depressive symptoms were assessed using the Beck Depression Inventory II. RESULTS: Ninety-one patients with dystonia participated (66 women, 25 men, mean age 60 ± 17 years). Nine subjects had generalized dystonia, 18 segmental dystonia and 64 had focal dystonia. Moderate to severe fatigue was present in 43% of the cohort (FSS), excessive daytime somnolence in 27% (ESS) and other sleep disturbances in 26% (PDSS). FSS and MFI scores correlated significantly with HRQOL even when controlled for depression and sleep disturbances. Excessive daytime somnolence and nocturnal sleep disturbances correlated significantly with the HRQOL; however, these effects were not seen for daytime somnolence when controlled for depression. Psychometric testing found adequate reliabilities and convergent validities for both fatigue and sleep scales. CONCLUSION:Fatigue and sleep disturbances revealed high prevalence rates in this large, first of its dystonia study. They negatively impacted the quality of life even when controlled for comorbid depression.
Authors: Mónica M Kurtis; Roberta Balestrino; Carmen Rodriguez-Blazquez; Maria João Forjaz; Pablo Martinez-Martin Journal: Front Neurol Date: 2018-05-29 Impact factor: 4.003
Authors: Melanie Leigh Supnet; Patrick Acuna; Samuel J Carr; Jan Kristoper de Guzman; Xena Al Qahtani; Trisha Multhaupt-Buell; Taylor Francoeur; Gabrielle E Aldykiewicz; Priyanka R Alluri; Lindsey Campion; Lisa Paul; Laurie Ozelius; Ellen B Penney; Christopher D Stephen; Marisela Dy-Hollins; Nutan Sharma Journal: Front Neurol Date: 2020-11-27 Impact factor: 4.003
Authors: Marenka Smit; Arwen S J Kamphuis; Anna L Bartels; Vladimir Han; Roy E Stewart; Inge Zijdewind; Marina A Tijssen Journal: Mov Disord Clin Pract Date: 2016-12-05
Authors: Lisa Klingelhoefer; Maximilian Kaiser; Anna Sauerbier; Robert Untucht; Miriam Wienecke; Könül Mammadova; Björn Falkenburger; Olaf Gregor; K Ray Chaudhuri; Heinz Reichmann Journal: J Neural Transm (Vienna) Date: 2020-11-04 Impact factor: 3.575